DK1082962T3 - Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B - Google Patents

Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B

Info

Publication number
DK1082962T3
DK1082962T3 DK99920872T DK99920872T DK1082962T3 DK 1082962 T3 DK1082962 T3 DK 1082962T3 DK 99920872 T DK99920872 T DK 99920872T DK 99920872 T DK99920872 T DK 99920872T DK 1082962 T3 DK1082962 T3 DK 1082962T3
Authority
DK
Denmark
Prior art keywords
hydroxy
activation
acid derivatives
inhibitors
trifluoromethylbenzoic acid
Prior art date
Application number
DK99920872T
Other languages
Danish (da)
English (en)
Inventor
Rafanell Julian Garcia
Roca Manuel Merlos
De Arriba Alberto Fernandez
De Maria Fernando Cavalcanti
Acosta Agusti Miralles
Crespo Mariano Sanchez
Dalmau Javier Forn
Original Assignee
Uriach & Cia Sa J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J filed Critical Uriach & Cia Sa J
Application granted granted Critical
Publication of DK1082962T3 publication Critical patent/DK1082962T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99920872T 1998-05-27 1999-05-26 Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B DK1082962T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009801154A ES2136581B1 (es) 1998-05-27 1998-05-27 Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
PCT/ES1999/000154 WO1999061030A1 (es) 1998-05-27 1999-05-26 USO DE DERIVADOS DEL ACIDO 2-HIDROXI-4-TRIFLUOROMETILBENZOICO COMO INHIBIDORES DE LA ACTIVACION DEL FACTOR DE TRANSCRIPCION NUCLEAR NF-λB

Publications (1)

Publication Number Publication Date
DK1082962T3 true DK1082962T3 (da) 2003-11-24

Family

ID=8304002

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99920872T DK1082962T3 (da) 1998-05-27 1999-05-26 Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B

Country Status (14)

Country Link
US (2) US6414025B1 (no)
EP (2) EP1082962B1 (no)
JP (1) JP2002516283A (no)
KR (2) KR100762156B1 (no)
AT (1) ATE245987T1 (no)
AU (1) AU3828699A (no)
BR (1) BR9911598A (no)
CA (1) CA2332863A1 (no)
DE (1) DE69910019T2 (no)
DK (1) DK1082962T3 (no)
ES (2) ES2136581B1 (no)
NO (1) NO20005981L (no)
PT (1) PT1082962E (no)
WO (1) WO1999061030A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2154242B1 (es) * 1999-09-03 2001-10-16 Uriach & Cia Sa J Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb.
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
ES2190373B1 (es) * 2001-12-07 2004-10-16 J. URIACH & CIA, S.A. Uso del acido 2-hidroxi- o 2-acetiloxi-4-trifluorometilbenzoico como agente para el tratamiento y prevencion del deterioro cognitivo ligero.
PL374700A1 (en) 2002-09-20 2005-10-31 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
LT2805720T (lt) 2008-05-28 2019-09-25 Reveragen Biopharma, Inc. Nehormoniniai steroidiniai nf-kb moduliatoriai, skirti ligoms gydyti
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
CN103665012B (zh) * 2013-12-06 2016-06-22 辽宁师范大学 新型三氟柳无机药物化合物及合成方法
US10799514B2 (en) 2015-06-29 2020-10-13 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
US20180016314A1 (en) * 2016-07-12 2018-01-18 Children's Hospital Medical Center Treatment of disease via transcription factor modulation
KR101975603B1 (ko) 2018-09-14 2019-08-28 이영문 조력 발전장치
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096252A (en) * 1976-06-10 1978-06-20 J. Uriach & Cia S.A. 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents
IT1276071B1 (it) * 1995-10-31 1997-10-24 Nicox Ltd Compositi ad attivita' anti-infiammatoria

Also Published As

Publication number Publication date
NO20005981L (no) 2000-12-12
NO20005981D0 (no) 2000-11-27
US6414025B1 (en) 2002-07-02
EP1082962B1 (en) 2003-07-30
PT1082962E (pt) 2003-11-28
DE69910019D1 (de) 2003-09-04
KR20070006943A (ko) 2007-01-11
AU3828699A (en) 1999-12-13
DE69910019T2 (de) 2004-05-06
ES2136581B1 (es) 2000-09-16
WO1999061030A1 (es) 1999-12-02
ES2204129T3 (es) 2004-04-16
KR20010052404A (ko) 2001-06-25
ATE245987T1 (de) 2003-08-15
CA2332863A1 (en) 1999-12-02
US6610745B2 (en) 2003-08-26
BR9911598A (pt) 2001-02-13
EP1082962A1 (en) 2001-03-14
KR100713601B1 (ko) 2007-05-02
ES2136581A1 (es) 1999-11-16
JP2002516283A (ja) 2002-06-04
US20030032630A1 (en) 2003-02-13
EP1362592A1 (en) 2003-11-19
KR100762156B1 (ko) 2007-10-04

Similar Documents

Publication Publication Date Title
BR9806752A (pt) Ftalazinonas.
DK1259218T3 (da) Kosmetisk sammensætning til behandling af aldrende og/eller stresset hud
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
JP2000503980A5 (no)
PT921785E (pt) Combinacao de enzimas protease acidas e tampoes acidicos e suas utilizacoes
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
DK1082962T3 (da) Anvendelse af 2-hydroxy-4-trifluormethylbenzoesyrederivater som inhibitorer af aktiveringen af de nukleare transskriptionsfaktorer NF-(K)B
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
DK0767798T3 (da) Sterolderivater anvendt til regulering af meiose
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DK1632248T3 (da) Anti-interleukin-9-antistof eller anti-interleukin-9-receptor-antistof til behandling af bronkial overfølsomhed
NO20032761D0 (no) Aktivitetsstyring ved diett
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
NO20014081L (no) Anvendelse av tianeptin i produksjonen av medikamenter til behandling av nevrodegenerative patologier
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
NO982562L (no) Sammensetning for behandling av smerte
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
WO1998052548A3 (de) Verwendung von 1-ar(alk)yl-imidazolin-2-one zur behandlung von angst- und spannungszuständen
ATE241640T1 (de) Fusidinsäure-derivate
BR0011742A (pt) Proteção bacteriana